Novel macrocyclic heteroaryl derivatives acting as non-receptor tyrosine-protein kinase TYK2 and/or JAK1 and/or JAK2 inhibitors have been reported in a Hangzhou Highlightll Pharmaceutical Co. Ltd. patent.

Hainan Simcere Pharmaceutical Co. Ltd. has patented new membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of breast cancer.

EA Pharma Co. Ltd. has described 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) inhibitors reported to be useful for the treatment of age-related issues, as well as inflammatory, metabolic, neurodegenerative, mitochondrial and renal diseases.

Alceptor Therapeutics Inc. has divulged α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.

Evotec International GmbH has synthesized integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.

Kalvista Pharmaceuticals Ltd. has identified coagulation factor XII (FXIIa) inhibitors reported to be useful for the treatment of hereditary angioedema, atherosclerosis, inflammatory disorders, neurodegeneration, diabetic retinopathy, SARS-CoV-2 infection (COVID-19), stroke and thrombotic disorders, among others.

A group of researchers have disclosed spike glycoprotein (SARS-CoV-2; COVID-19 virus)/ACE2 interaction inhibitors in a new patent.

Vanderbilt University has described muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, sleep disorders and cognitive disorders.

Gandeeva Therapeutics Inc. has divulged serine/threonine-protein kinase B-raf (BRAF)/MAP2K1 (MEK1) interaction stabilizers reported to be useful for the treatment of brain metastasis.

MD Biopharm Co. Ltd. has identified compounds acting as mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) and kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, viral infection, Parkinson’s disease, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) and tuberculosis.